RecruitingNot ApplicableNCT07311434

Sleep and Morning Wellbeing Study

Evaluation of Perceived Outcomes With AGZ: A Randomized, Controlled, Consumer Perception Study


Sponsor

Athletic Greens International

Enrollment

300 participants

Start Date

Jan 20, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The study will be a prospective randomized, controlled clinical study. There will be interventional treatment for a total of 30 days. The subjects will complete questionnaires throughout the study at pre-specified timepoints.


Eligibility

Min Age: 22 YearsMax Age: 59 Years

Inclusion Criteria12

  • Male or female.
  • Age 25-59 years.
  • BMI ≥18.5 and ≤29.9 kg/m².
  • Currently experiencing issues with sleep quality, falling asleep, staying asleep, or waking during the night.
  • RU-SATED score ≤17.
  • Willing and able to follow the study protocol.
  • Willing to discontinue any other supplements (including nootropics, adaptogens, calming herbs), medications, herbal remedies, or over-the-counter sleep medications (e.g., zolpidem, diphenhydramine, Benadryl, ZzzQuil, Unisom, magnesium or melatonin products) used to assist with sleep during the study.
  • Agree to limit alcohol intake within approximately 4 hours of bedtime throughout participation.
  • Agree to limit caffeine intake to ≤400 mg/day (about 3-4 cups of coffee) and avoid ingestion of caffeine-containing products after 2:00 PM during the study period.
  • Generally healthy and not living with any uncontrolled chronic disease.
  • Resides in the United States.
  • Willing to discontinue any restricted products and adhere to all required study assessments.

Exclusion Criteria19

  • Diagnosed chronic sleep conditions (e.g., insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome, sleep apnea).
  • Current use of sleep-tracking technology (e.g., wrist-worn trackers, rings, smartphone apps) that could influence sleep behavior or perception.
  • Women currently undergoing perimenopause or experiencing vasomotor symptoms (e.g., night sweats).
  • Use of hormone therapy (estrogen, progesterone, phytoestrogens) within the last 3 months.
  • Diagnosed psychiatric disorders including major depressive disorder with acute symptoms, bipolar disorder, generalized anxiety disorder with active symptoms, and PTSD with frequent nightmares.
  • Diagnosed neurodegenerative or chronic pain disorders, including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia.
  • Regular prescribed stimulant use (e.g., amphetamines such as Adderall/Vyvanse; methylphenidate such as Ritalin/Concerta; modafinil/armodafinil).
  • Current use of CNS-activating antidepressants (bupropion, fluoxetine, venlafaxine, sertraline).
  • Current or recent use of cannabis or THC-containing products (recreational or medicinal marijuana, CBD with measurable THC, synthetic cannabinoids) within the past 30 days.
  • Employment in jobs disrupting nighttime sleep (e.g., night shift, rotating shift, excessive travel).
  • Current use of prescription sleep aids.
  • Introduction of any new sleep-related supplements, medications, herbal remedies, or melatonin products during the study.
  • Use of any prescription or OTC products with sedative properties (e.g., melatonin, diphenhydramine, doxylamine, valerian, ZzzQuil, Advil PM) within 4 weeks prior to enrollment or habitual use ≥3 times per week prior to enrollment unless investigator-approved.
  • Allergy or sensitivity to any study product ingredients.
  • Pregnant, breastfeeding, or trying to conceive during the study period.
  • History of substance abuse.
  • Heavy alcohol use (≥8 drinks/week for women or ≥15 drinks/week for men).
  • Participation in another research study now or within the next 7 weeks.
  • Any condition or behavior that, in the investigator's judgment, may interfere with study participation or data integrity.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTSleep Supplement

Powdered sleep supplement


Locations(1)

Alethios (Virtual Study Platform)

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07311434


Related Trials